Application of arginine in preparation of medicine for preventing and treating kidney injury caused by zoledronic acid

By adding arginine to the drug and combining zoledronic acid, the kidney damage caused by bisphosphonate drugs was solved, which significantly reduced nephrotoxicity-related indicators and inflammatory factors, improved cell viability, and improved osteoporosis renal injury during treatment.

CN118903090APending Publication Date: 2024-11-08CHONGQING MEDICAL UNIVERSITY
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411196488.X
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-28
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

Existing bisphosphonate drugs such as zoledronic acid often cause kidney damage in the treatment of osteoporosis, and there are no effective prevention and treatment measures.

Method used

Arginine is used as the active ingredient, and a drug combination containing arginine and zoledronic acid is prepared to prevent and treat renal damage caused by zoledronic acid. The specific dose is 750-4500 mg/kg body weight, and the mass ratio is 1: 150~600, used to reduce urea and creatinine levels and reduce the inflammatory factor TNFα level.

Benefits of technology

Significantly alleviates and improves pathological damage caused by zoledronic acid, reduces blood biochemical indicators related to nephrotoxicity, improves podocyte viability, reduces oxidative stress and inflammatory response, and effectively prevents and treats kidney damage caused by zoledronic acid and diabetes. .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005021277060000061
    Figure BDA0005021277060000061
  • Figure BDA0005021277060000071
    Figure BDA0005021277060000071
  • Figure BDA0005021277060000072
    Figure BDA0005021277060000072
Patent Text Reader

Abstract

The invention relates to the technical field of biology, in particular to application of arginine to preparation of a medicine for preventing and treating kidney injury caused by zoledronic acid. The research finds that arginine can effectively relieve and improve pathological and biochemical indexes of renal injury occurring in the treatment process by using zoledronic acid, which indicates that arginine has good treatment and prevention effects on renal injury caused by zoledronic acid. Besides, the arginine can also relieve high-glucose-induced podocyte oxidative stress and inflammatory response and improve podocyte activity, which indicates that the arginine also has a good treatment effect on kidney injury caused by diabetes mellitus.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the field of biotechnology, and in particular to application of arginine in preparing a medicine for preventing and treating kidney damage caused by zoledronic acid. Background Art

[0002] Osteoporosis (OP) is a metabolic disease caused by multiple complex factors including endocrine, nutritional, immune and genetic factors. It is a systemic bone disease characterized by decreased bone mass, damage to bone tissue microstructure, increased bone fragility and susceptibility to fractures. Osteoporosis is divided into two categories: primary osteoporosis and secondary osteoporosis. Among them, primary osteoporosis includes postmenopausal osteoporosis (type I), senile osteoporosis (type II) and idiopathic osteoporosis (including adolescent type). Secondary osteoporosis refers to osteoporosis caused by any disease and / or drug that affects bone metabolism and other clear causes.

[0003] Primary osteoporosis can be alleviated by drug treatment. Current anti-osteoporosis drugs are divided into the following categories according to their mechanism of action: bone resorption inhibitors, bone formation promoters, dual-acting drugs, other mechanism drugs and Chinese patent medicines. Bone resorption inhibitors include bisphosphonates, RANKL monoclonal antibodies (denosumab), selective estrogen receptor modulators (SERMs) and calcitonin. Bone formation promoters include parathyroid hormone (PTH) and PTH-related protein (PTHrP). Dual-acting drugs include the sclerostin monoclonal antibody romosuzumab. Other mechanism drugs include active vitamin D and its analogs and vitamin K2 [3] .

[0004] The clinical application of bisphosphonates in the treatment of osteoporosis began in the 1990s and has undergone three generations of drug development. The first generation of representative drugs is etidronate, clodronate, and tiludronate; the second generation of products is pamidronate and alendronate; the third generation of products includes ibandronate, risedronate, and zoledronate. Currently, the above representative drugs are available in China.

[0005] Zoledronic acid is a third-generation bisphosphonate drug that inhibits bone resorption and reduces bone turnover by inhibiting osteoclast activity and inducing osteoclast apoptosis. It can significantly reduce the risk of fractures in postmenopausal osteoporosis patients and increase bone density. It is the most effective bisphosphonate drug for preventing vertebral fractures. About 1 / 3 of patients experience adverse reactions in people using zoledronic acid. The most common adverse reactions are flu-like symptoms, including bone pain, fever, fatigue, chills, arthralgia and myalgia, arthritis, and secondary joint swelling. These reactions usually occur within 3 days of administration and usually resolve within a few days. A small number of patients may also experience symptoms such as decreased plasma phosphate levels (about 20% of patients), nausea (about 5.8%), and vomiting (about 2.6%). It is reported that osteonecrosis of the jaw occurs mainly in cancer patients receiving intravenous bisphosphonates. [4] In addition, there are several reports in the literature on cases of zoledronic acid-induced renal injury.

[0006] There are many causes of renal injury. In addition to zoledronic acid, there are many drugs or causes that can cause renal injury, such as antibiotics, anticancer drugs (such as paclitaxel) and other drugs that are metabolized by the kidneys. If taken for a long time or in large doses, they will cause certain damage to the kidneys. Long-term hyperglycemia can damage the blood vessels and cells of the kidneys, leading to a gradual decline in renal function. Sustained hypertension can increase the pressure of the renal blood vessels, leading to damage to the structure and function of the kidneys. In addition, trauma such as car accidents and falls from heights can also cause renal trauma. Due to the different causes of renal injury, there are certain differences in subsequent treatment methods. Therefore, it is necessary to select corresponding therapeutic drugs according to the disease causes of renal injury. For example, for renal injury caused by clinical hyperlipidemia, statins are selected to lower lipids and protect the kidneys. For example, if renal injury is caused by renal diseases, common drugs for treating renal diseases such as benazepril hydrochloride, captopril, and losartan potassium can be selected in the milder stage of the disease. At present, the exact mechanism of renal injury caused by bisphosphonates is unclear. So far, no drug has been found that can effectively treat or prevent renal injury caused by zoledronic acid. Summary of the invention

[0007] In view of this, the present invention provides the use of arginine in the preparation of a drug for preventing and treating renal injury caused by zoledronic acid. Studies have shown that arginine has a good preventive and therapeutic effect on renal injury caused by zoledronic acid.

[0008] In order to achieve the above-mentioned object of the invention, the present invention provides the following technical solutions:

[0009] Application of arginine in the preparation of medicines for preventing and treating renal injury.

[0010] Renal injury refers to the abnormal changes in the structure and function of the kidney caused by various factors. In the present invention, renal injury mainly refers to renal injury caused by drugs or pathology, among which drug-induced renal injury is also called nephrotoxicity.

[0011] In some embodiments, the renal injury is renal injury caused by zoledronic acid (i.e., nephrotoxicity); wherein, arginine prevents and treats renal injury caused by zoledronic acid, which means that arginine antagonizes renal injury caused by zoledronic acid. The prevention and treatment includes: improving pathological damage to the kidney and / or reducing the level of blood biochemical indicators related to nephrotoxicity.

[0012] Among them, the pathological damage of the kidney includes at least one of the following: dark red urine, slight to mild inflammatory cell infiltration in the renal cortex / capsule / renal papilla, mild basophilic tubules in the cortex, mild to obvious dilation and slight to obvious degeneration / necrosis of the renal tubules, and moderate to obvious casts in the cortex / medullary.

[0013] The regulation of blood biochemical indicators related to nephrotoxicity includes: reducing urea and / or creatinine levels, and / or reducing inflammatory factor levels.

[0014] More specifically, the inflammatory factor level includes TNFα.

[0015] In the above application provided by the present invention, the active ingredient of the drug is arginine, and the effective dose of the arginine is 750-4500 mg / kg body weight.

[0016] In the above application of the present invention, the active ingredients of the drug include arginine and zoledronic acid. The mass ratio of zoledronic acid to arginine is 1:150-600, and can be specifically 1:150, 1:300, or 1:600.

[0017] In other embodiments, studies have shown that arginine has a good preventive and therapeutic effect on renal damage caused by diabetes. Therefore, the present invention also provides the use of arginine in the preparation of a drug for preventing and treating renal damage caused by diabetes. The prevention and treatment includes: improving podocyte activity, reducing the level of oxidative stress markers, promoting the level of podocyte anti-inflammatory factors and / or inhibiting the level of podocyte pro-inflammatory factors.

[0018] The oxidative stress markers include ROS.

[0019] The podocyte pro-inflammatory factors include IL-6; the podocyte anti-inflammatory factors include IL-10.

[0020] In the application of arginine provided by the present invention in the preparation of a drug for preventing and treating kidney damage caused by diabetes, the active ingredient of the drug is arginine. Further, the concentration of the arginine is 0.5-1.5 mM, specifically 0.5 mM, 1 mM, 1.5 mM.

[0021] In the above application, the arginine is L-arginine, D-arginine or DL-arginine. In a specific embodiment of the present invention, the arginine is L-arginine.

[0022] The present invention also provides a pharmaceutical composition for preventing renal damage caused by zoledronic acid, comprising arginine and zoledronic acid, wherein the mass ratio of zoledronic acid to arginine is 1:150-600, and specifically 1:150, 1:300, or 1:600.

[0023] The present invention also provides a method for treating and / or preventing renal damage caused by zoledronic acid, comprising: administering arginine, or administering a composition of arginine and zoledronic acid. Further, in the composition, the mass ratio of zoledronic acid to arginine is 1:150 to 600; specifically, it can be 1:150, 1:300, or 1:600.

[0024] The present invention also provides a method for treating and / or preventing kidney damage caused by diabetes, comprising: administering arginine. The administration concentration of the arginine is 0.5-1.5 mM, specifically 0.5 mM, 1 mM, 1.5 mM.

[0025] In the application and method of the present invention, arginine and zoledronic acid are administered simultaneously. In order to improve the compliance of patients, the present invention prepares arginine and zoledronic acid into a compound preparation, that is, the two exist in the same preparation in the form of a mixture.

[0026] In the present invention, the prevention and treatment include prevention and treatment. The simultaneous administration of arginine and zoledronic acid can be used to prevent the occurrence of renal damage caused by zoledronic acid. The administration of arginine after zoledronic acid can be used to treat renal damage caused by zoledronic acid and renal damage caused by diabetes. The administration of arginine after high sugar induction can treat renal damage caused by diabetes, and the administration before high sugar induction can prevent renal damage caused by diabetes. The object of the prevention and treatment is a human or a mammal, and the mammal includes species common in the art, including but not limited to cattle, horses, sheep, pigs, dogs, cats, rodents and primates. The prevention and treatment effect is particularly obvious for women or female mammals.

[0027] The present invention has found that arginine can effectively reduce and improve the pathological damage of renal injury that occurs during the treatment with zoledronic acid; and reduce the levels of blood biochemical indicators related to nephrotoxicity, such as urea, creatinine and / or reduce the levels of inflammatory factors (such as TNFα). It shows that arginine has a good therapeutic and preventive effect on renal injury caused by zoledronic acid. In addition, arginine can also reduce the oxidative stress and inflammatory response of podocytes induced by high sugar, and improve the activity of podocytes, indicating that arginine also has a good therapeutic effect on renal injury caused by diabetes. BRIEF DESCRIPTION OF THE DRAWINGS

[0028] Figure 1 Arginine improves the renal toxicity of Kunming mice treated with zoledronic acid; changes in body weight (A), survival (B), urea nitrogen (C) and serum creatinine (D) were recorded after intraperitoneal injection of the drug;

[0029] Figure 2 Arginine improves the renal toxicity of SD rats treated with zoledronic acid; the changes of body weight (A, B), urea nitrogen (C) and serum creatinine (D) on the 8th day were recorded after intravenous injection of the drug;

[0030] Figure 3 Arginine inhibited the level of inflammatory factor TNF-α in KM mice induced by zoledronic acid;

[0031] Figure 4 Arginine inhibits the level of inflammatory factor TNF-α in Balb / c mice induced by zoledronic acid;

[0032] Figure 5 Arginine improves high glucose-induced podocyte injury;

[0033] Figure 6 Arginine alleviates high glucose-induced oxidative stress in podocytes;

[0034] Figure 7 These results showed that arginine alleviated the levels of inflammatory factors in podocytes induced by high glucose. DETAILED DESCRIPTION

[0035] The present invention provides the use of arginine in the preparation of a medicine for preventing and treating renal injury caused by zoledronic acid. Those skilled in the art can refer to the content of this article and appropriately improve the process parameters to achieve it. It is particularly important to point out that all similar replacements and modifications are obvious to those skilled in the art, and they are all considered to be included in the present invention. The method and application of the present invention have been described by preferred embodiments, and relevant personnel can obviously modify or appropriately change and combine the method and application of this article without departing from the content, spirit and scope of the present invention to realize and apply the technology of the present invention.

[0036] The test materials used in the present invention are all common commercial products and can be purchased in the market.

[0037] The present invention will be further described below in conjunction with embodiments:

[0038] Example 1

[0039] (I) Kunming mouse animal experiment

[0040] First, we injected an excessive dose of zoledronic acid (30 mg / kg) into Kunming mice intraperitoneally to simulate the side effects of zoledronic acid, thereby establishing an animal model for evaluating the effect of improved formulations. At the same time, we prepared an improved formulation of zoledronic acid with a formula of zoledronic acid: L-arginine = 1:150, in order to reduce the side effects of zoledronic acid in clinical use.

[0041] We then injected the modified zoledronic acid formulation into Kunming mice through intraperitoneal injection, observed and recorded the survival and weight changes of Kunming mice, and detected renal toxicity-related indicators such as urea and creatinine in Kunming mice. Figure 1 :

[0042] Kunming mice were randomly divided into 3 groups (8-week-old females, 25±3g): NS, ZOL, ZOL:L-Arg=1:150, 5 mice in each group. Among them, the ZOL:L-Arg group was administered with a dose of 30mg / kgZOL+4500mg / kgL-Arg, and the drug was intraperitoneally injected only on the first day, and no further administration was performed. After intraperitoneal injection of the drug, changes in body weight (A), survival (B), urea nitrogen (C), and serum creatinine (D) were recorded. Data analysis was performed using GraphPad Prism 8.

[0043] Compared with the zoledronic acid model group, the modified zoledronic acid preparation prepared by adding L-Arg can effectively inhibit the side effects of zoledronic acid preparation in animal models, alleviate the weight loss of Kunming mice, and effectively reduce the mortality rate of experimental animals. In addition, compared with the zoledronic acid model group, the zoledronic acid preparation modified by L-Arg can significantly reduce urea nitrogen and blood creatinine levels.

[0044] The above results show that during the experiment, weight loss, death and blood biochemical (urea nitrogen and blood creatinine) changes in Kunming mice were related to intraperitoneal injection of zoledronic acid, while the use of the improved preparation can effectively alleviate the weight loss and death of mice, and blood biochemical indicators further prove that L-Arg treatment can effectively alleviate the renal toxicity caused by zoledronic acid.

[0045] (II) Sprague-Dawley rat animal experiment

[0046] First, we injected zoledronic acid (5 mg / kg) into SD rats intravenously to simulate the side effects of zoledronic acid, thereby establishing an animal model for evaluating the effect of formulation improvement. At the same time, we prepared a variety of formulations, in which the mass ratio of the two components in the formulation was ZOL:L-Arg=1:150, ZOL:L-Arg=1:300, and ZOL:L-Arg=1:600. In order to reduce the side effects of zoledronic acid in clinical use.

[0047] The dosage of ZOL:L-Arg (1:150) group was: 5 mg / kg ZOL + 750 mg / kg L-Arg;

[0048] The ZOL:L-Arg (1:300) group was administered with the following dosages: 5 mg / kg ZOL + 1500 mg / kg L-Arg;

[0049] The dosage of ZOL:L-Arg (1:600) group was: 5mg / kgZOL+3000mg / kgL-Arg.

[0050] We then injected the modified zoledronic acid formulation into SD rats intravenously and observed and recorded the changes in the rats' body weight, blood cell count, and blood biochemistry. The results are shown in Tables 1-2 and Figure 2 :

[0051] (1) Weight statistics

[0052] Table 1

[0053]

[0054] Note: "*" indicates p≤0.05 compared with the negative control group of the same sex during the same period; "↓" indicates a decrease. Groups 1 to 6 are negative control group, ZOL:L-Arg (1:150) group, ZOL:L-Arg (1:300) group, ZOL:L-Arg (1:600) group, zoledronic acid (5 mg / kg) group and arginine (3000 mg / kg) group.

[0055] (2) Blood cell count statistics

[0056] Table 2

[0057]

[0058] Note: "*" indicates p≤0.05 compared with the negative control group of the same sex during the same period; "↓" indicates a decrease. Groups 1 to 6 are negative control group, ZOL:L-Arg (1:150) group, ZOL:L-Arg (1:300) group, ZOL:L-Arg (1:600) group, zoledronic acid (5 mg / kg) group and arginine (3000 mg / kg) group.

[0059] (3) Blood biochemical statistics

[0060] Table 3

[0061]

[0062]

[0063] Note: "*" indicates p≤0.05 compared with the negative control group of the same sex during the same period; "↑" indicates an increase, and "↓" indicates a decrease. Groups 1 to 6 are the negative control group, ZOL:L-Arg (1:150) group, ZOL:L-Arg (1:300) group, ZOL:L-Arg (1:600) group, zoledronic acid (5 mg / kg) group, and arginine (3000 mg / kg) group, respectively.

[0064] During the experiment, compared with the negative control group of the same sex during the same period, the animals in the low, medium and high doses of arginine groups and the zoledronic acid group had a decrease in body weight after the first dose. One week after the last dose, the body weight was still lower than that of the negative control group of the same sex during the same period, but the body weight gain was similar to that of the negative control group of the same sex during the same period; the body weight change trend of the component two groups was similar to that of the negative control group of the same sex during the same period. The decrease in body weight was related to the intravenous injection of zoledronic acid, but the administration of arginine had a detoxifying effect on zoledronic acid.

[0065] During the trial, compared with the negative control group of the same sex during the same period, the blood biochemistry (creatinine and urea) of the animals in each treatment group showed drug-related changes. A total of 8 animals (4 / 5♂, 4 / 5♀) in the zoledronic acid group were found dead on D7, D10 and D13. Dark red urine was observed in clinical observations after the animals were administered until death. Microscopically, slight to mild inflammatory cell infiltration in the renal cortex, capsule / renal papilla, mild basophilic tubules in the cortex, mild to obvious dilation of the renal tubules, slight to obvious degeneration / necrosis, moderate to obvious casts in the cortex / medullary, and changes in blood biochemical indicators (UREA and Cre increased) were observed. The administration of arginine can reduce the pathological changes and related biochemical indicators of renal injury in rats.

[0066] SD rats were randomly divided into 6 groups (female and male): NS, ZOL, ZOL:L-Arg=1:150, ZOL:L-Arg=1:300, ZOL:L-Arg=1:600, 5 males and 5 females in each group, a total of 10 rats. After intravenous injection of drugs, the changes of body weight (A, B), urea nitrogen (C) and serum creatinine (D) on the 8th day were recorded. Data analysis was performed using GraphPadPrism 8.

[0067] (III) Elisa detection of TNF-α levels

[0068] (1) Experimental groups:

[0069] Control: saline (Balb / c, half male and half female, 10 total, KM, half male and half female, 10 total);

[0070] Model: 0.75 mg / ml zoledronic acid (Balb / c, half male and half female, 10 total, KM, half male and half female, 10 total);

[0071] Intervention group: Zoledronic acid: L-arginine = 1:150 (Balb / c half male and half female, 10 total, KM half male and half female, 10 total)

[0072] (2) Experimental steps:

[0073] The mice were collected, the drugs were injected on the first day, and all the blood was collected on the fourth day, centrifuged, and the plasma was used for Elisa. Detection index: TNF-α.

[0074] (3) Elisa test method:

[0075] 1. Reagent preparation: prepare various test reagents, diluted standards and samples to be tested.

[0076] 2. Determine the enzyme label strips: Calculate the enzyme label strips required for the sample and standard to be tested, take the enzyme label strips out of the aluminum foil bag, put the remaining enzyme label strips back into the aluminum foil bag and seal the bag.

[0077] Keep at low temperature.

[0078] 3. Soak the ELISA plate: Add 1× washing solution (350μL / well) to soak the ELISA plate, let it stand for 30 seconds, discard the liquid in the well, and pat the ELISA plate dry. The amount of liquid has an important impact on the test results. Make sure there is no washing solution left in the last pat.

[0079] 4. Sample addition and incubation: Add each gradient standard and diluted sample to be tested, 100 μL / well, ensure that the sample is added within 15 minutes, and incubate at room temperature for 2 hours.

[0080] 5. Wash the ELISA plate: discard the liquid in the wells, add 1× washing solution (350 μL / well) to wash the plate 5 times, and pat the ELISA plate dry.

[0081] 6. Detection antibody incubation: Add the detection antibody prepared in advance to the working concentration to the ELISA plate, 100 μL / well, and incubate at room temperature for 2 hours.

[0082] 7. Wash the ELISA plate: discard the liquid in the wells, add 1× washing solution (350 μL / well) to wash the plate 5 times, and pat the ELISA plate dry.

[0083] 8. Enzyme conjugate incubation: Add the enzyme conjugate prepared in advance to the working concentration to the ELISA plate, 100 μL / well, and incubate at room temperature for 20 minutes.

[0084] 9. Wash the ELISA plate: discard the liquid in the wells, add 1× washing solution (350 μL / well) to wash the plate 5 times, and pat the ELISA plate dry.

[0085] 10. Color development: Return the substrate solution to room temperature 10 minutes before use, add the substrate solution to the ELISA plate, 100 μL / well, and incubate at room temperature in the dark for 15 minutes.

[0086] 11. Stop: Add 50 μL / well stop solution to the ELISA plate. The color will turn from blue to yellow. Gently shake the ELISA plate until the color is uniform.

[0087] 12. Reading: Read the light absorption value at 450nm / 630nm within 10 minutes. Calculate the concentration of TNF-α. Figures 3-4 .

[0088] (4) Results analysis

[0089] The results showed that arginine could significantly inhibit the increase in the level of inflammatory factor TNF-α caused by zoledronic acid, and improve the renal damage caused by zoledronic acid-induced inflammatory response, especially in female mice.

[0090] (IV) Verification of the efficacy of arginine on diabetic kidney damage—MPC-5 cell experiment

[0091] 1. Construction of cell model: The diabetic nephropathy cell model was simulated by treating mouse kidney podocyte MPC-5 cells with high glucose (40mM). After high glucose treatment, the cells showed: (1) decreased cell viability; (2) decreased expression of podocin protein, which is involved in the normal development of the glomerular filtration barrier and maintains its function; (3) significantly increased levels of oxidative stress and inflammatory markers. This indicates that a cell model that reflects diabetic kidney damage has been successfully established and used to evaluate the effect of arginine on kidney damage.

[0092] 2. Efficacy of arginine on diabetic kidney damage

[0093] (1) Arginine improves high glucose-induced podocyte injury

[0094] First, cells were treated with different concentrations of arginine (0, 0.1, 0.5, 1, 2, 5, 10, 15, 20 mM) for 24 h, and CCK-8 was used to screen out the safety of arginine treatment at low, medium, and high doses of 0.5, 1, and 1.5 mM. Then, MPC-5 cells were cultured in 12-well plates, and cell viability was evaluated 24 h after different treatments. The dosages are shown in Table 4, and the results are shown in Table 4. Figure 5 :

[0095] Table 4

[0096]

[0097] After 24 hours of high-sugar treatment, the cell viability of podocytes decreased significantly compared with the control group. The cell viability of the low, medium and high dose arginine groups was significantly improved compared with the soup group, and the effect was similar to that of the hypoglycemic drug metformin treatment group, indicating that arginine treatment can improve the cell viability of diabetic nephropathy models. At the same time, it was observed that the expression of podocin protein increased in a dose-dependent manner in the arginine treatment group, among which the increase in podocin protein level in the high-dose arginine group was more obvious than that in the metformin treatment group, indicating that arginine treatment can promote the normal development of the glomerular filtration barrier and maintain its function.

[0098] (2) Arginine reduces high glucose-induced oxidative stress in podocytes

[0099] By using the DCFH-DA probe for reactive oxygen species (ROS) fluorescence staining, it was observed that after high glucose treatment, the intracellular ROS level increased significantly, and arginine could reverse the increase of ROS in podocytes induced by high glucose, and its induction effect in the high-dose group was better than that in the metformin treatment group, indicating that arginine can reduce high glucose-induced podocyte oxidative stress and improve renal damage caused by high glucose-induced oxidative stress. Figure 6 .

[0100] (3) Arginine reduces the level of inflammatory factors in podocytes induced by high glucose

[0101] Oxidative stress usually triggers inflammation, leading to the release of inflammatory cytokines. By detecting inflammatory cytokines, it was observed that high glucose upregulates the expression of the pro-inflammatory cytokine IL-6 and downregulates the expression of the anti-inflammatory cytokine IL-10. Arginine can significantly inhibit the expression of IL-6 and increase the level of IL-10, and its induction effect in the high-dose group is better than that in the metformin treatment group, see Figure 7 .

[0102] 3. Experimental results and analysis

[0103] Through the analysis of experimental results, arginine treatment can improve podocyte viability, reduce the levels of oxidative stress markers, and alleviate inflammatory response (reduce the level of proinflammatory factor IL-6 and increase the level of anti-inflammatory factor IL-10), further reflecting the potential of arginine to treat diabetic nephropathy by protecting podocytes from high glucose-induced oxidative stress and damage.

[0104] The above are only preferred embodiments of the present invention. It should be pointed out that, for ordinary technicians in this technical field, several improvements and modifications can be made without departing from the principles of the present invention. These improvements and modifications should also be regarded as the scope of protection of the present invention.

Claims

1. Application of arginine in the preparation of drugs for preventing and treating renal damage caused by zoledronic acid.

2. The use according to claim 1, characterized in that: The prevention and treatment include: improving the pathological damage of the kidney and / or regulating the levels of blood biochemical indicators related to nephrotoxicity.

3. The use according to claim 2, characterized in that: The pathological damage of the kidney includes at least one of the following: dark red urine, slight to mild inflammatory cell infiltration in the renal cortex / capsule / renal papilla, mild basophilic tubules in the cortex, mild to obvious dilation, slight to obvious degeneration / necrosis of the renal tubules, and moderate to obvious casts in the cortex / medullary area; The regulation of blood biochemical indicators related to nephrotoxicity includes: reducing urea and / or creatinine levels, and / or reducing inflammatory factor levels.

4. The use according to claim 3, characterized in that: The inflammatory factors include TNFα.

5. The use according to any one of claims 1 to 4, characterized in that: The active ingredient of the medicine is arginine, or a combination of arginine and zoledronic acid.

6. The use according to claim 5, characterized in that: In the composition, the mass ratio of zoledronic acid to arginine is 1:150-600.

7. Use of arginine in the preparation of drugs for preventing and treating kidney damage caused by diabetes; The control includes: Improve podocyte viability, reduce the levels of oxidative stress markers, promote the levels of podocyte anti-inflammatory factors and / or inhibit the levels of podocyte pro-inflammatory factors.

8. The use according to claim 7, characterized in that: The oxidative stress markers include ROS; the podocyte pro-inflammatory factors include IL-6; and the podocyte anti-inflammatory factors include IL-10.

9. The use according to any one of claims 1 to 8, characterized in that: The arginine is L-arginine, D-arginine or DL-arginine.

10. A pharmaceutical composition for preventing renal damage caused by zoledronic acid, characterized in that: The invention comprises arginine and zoledronic acid; the mass ratio of the zoledronic acid to the arginine is 1:150-600.